Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2012 1
2013 2
2014 3
2015 3
2016 3
2017 2
2018 5
2019 10
2020 13
2021 15
2022 10
2023 15
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for chu qian tu
Your search for Chuiqian Tu retrieved no results
Notch signaling pathway: architecture, disease, and therapeutics.
Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu K, Chu Q. Zhou B, et al. Among authors: chu q. Signal Transduct Target Ther. 2022 Mar 24;7(1):95. doi: 10.1038/s41392-022-00934-y. Signal Transduct Target Ther. 2022. PMID: 35332121 Free PMC article. Review.
In this review, we focus on both classical and the latest findings related to NOTCH signaling to illustrate the history, architecture, regulatory mechanisms, contributions to physiological development, related diseases, and therapeutic applications of the NOTCH pathway. Th …
In this review, we focus on both classical and the latest findings related to NOTCH signaling to illustrate the history, architecture, regul …
Gut microbiome and cancer immunotherapy.
Li W, Deng Y, Chu Q, Zhang P. Li W, et al. Among authors: chu q. Cancer Lett. 2019 Apr 10;447:41-47. doi: 10.1016/j.canlet.2019.01.015. Epub 2019 Jan 23. Cancer Lett. 2019. PMID: 30684593 Free article. Review.
Accumulating evidence supports that microbiome affects the therapeutic efficacy of cancer immunotherapy, particularly immune checkpoint inhibitors. ...Also, we briefly introduce the relevant challenges that affect the therapeutic efficacy and present the possible so …
Accumulating evidence supports that microbiome affects the therapeutic efficacy of cancer immunotherapy, particularly immune checkpoi …
Exploiting innate immunity for cancer immunotherapy.
Yi M, Li T, Niu M, Mei Q, Zhao B, Chu Q, Dai Z, Wu K. Yi M, et al. Among authors: chu q. Mol Cancer. 2023 Nov 27;22(1):187. doi: 10.1186/s12943-023-01885-w. Mol Cancer. 2023. PMID: 38008741 Free PMC article. Review.
Considering that the innate arm is the cornerstone of the antitumor immune response, utilizing innate immunity provides potential therapeutic options for cancer control. Up to now, strategies exploiting innate immunity, such as agonists of stimulator of interferon genes, C …
Considering that the innate arm is the cornerstone of the antitumor immune response, utilizing innate immunity provides potential therape …
Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer.
Zhang H, Yang Y, Li X, Yuan X, Chu Q. Zhang H, et al. Among authors: chu q. Biomed Pharmacother. 2023 Mar;159:114248. doi: 10.1016/j.biopha.2023.114248. Epub 2023 Jan 14. Biomed Pharmacother. 2023. PMID: 36645960 Free article. Review.
Thus, Notch signaling is under active exploration as a potential therapeutic target in SCLC. Herein, we summarized and updated the functional relevance of Notch signaling in SCLC, discussed Notch signaling-targeted therapy for SCLC and the correspondent preclinical and cli …
Thus, Notch signaling is under active exploration as a potential therapeutic target in SCLC. Herein, we summarized and updated the fu …
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy.
Niu M, Yi M, Wu Y, Lyu L, He Q, Yang R, Zeng L, Shi J, Zhang J, Zhou P, Zhang T, Mei Q, Chu Q, Wu K. Niu M, et al. Among authors: chu q. J Hematol Oncol. 2023 Aug 12;16(1):94. doi: 10.1186/s13045-023-01487-5. J Hematol Oncol. 2023. PMID: 37573354 Free PMC article.
BACKGROUND: Recently, therapeutic antibodies against programmed cell death 1 (PD-1) and its ligand (PD-L1) have exerted potent anticancer effect in a variety of tumors. ...
BACKGROUND: Recently, therapeutic antibodies against programmed cell death 1 (PD-1) and its ligand (PD-L1) have exerted potent antica …
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease.
Zhou C, Qin Y, Zhao W, Liang Z, Li M, Liu D, Bai L, Chen Y, Chen Y, Cheng Y, Chu T, Chu Q, Deng H, Dong Y, Fang W, Fu X, Gao B, Han Y, He Y, Hong Q, Hu J, Hu Y, Jiang L, Jin Y, Lan F, Li Q, Li S, Li W, Li Y, Liang W, Lin G, Lin X, Liu M, Liu X, Liu X, Liu Z, Lv T, Mu C, Ouyang M, Qin J, Ren S, Shi H, Shi M, Su C, Su J, Sun D, Sun Y, Tang H, Wang H, Wang K, Wang K, Wang M, Wang Q, Wang W, Wang X, Wang Y, Wang Z, Wang Z, Wu L, Wu D, Xie B, Xie M, Xie X, Xie Z, Xu S, Xu X, Yang X, Yin Y, Yu Z, Zhang J, Zhang J, Zhang J, Zhang X, Zhang Y, Zhong D, Zhou Q, Zhou X, Zhou Y, Zhu B, Zhu Z, Zou C, Zhong N, He J, Bai C, Hu C, Li W, Song Y, Zhou J, Han B, Varga J, Barreiro E, Park HY, Petrella F, Saito Y, Goto T, Igai H, Bravaccini S, Zanoni M, Solli P, Watanabe S, Fiorelli A, Nakada T, Ichiki Y, Berardi R, Tsoukalas N, Girard N, Rossi A, Passaro A, Hida T, Li S, Chen L, Chen R. Zhou C, et al. Among authors: chu q. Transl Lung Cancer Res. 2023 Aug 30;12(8):1661-1701. doi: 10.21037/tlcr-23-339. Epub 2023 Aug 24. Transl Lung Cancer Res. 2023. PMID: 37691866 Free PMC article. Review.
Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.
Zhang S, Wang W, Xu C, Zhang Y, Cai X, Wang Q, Song Z, Li Z, Yu J, Zhong W, Wang Z, Liu J, Liu A, Li W, Zhan P, Liu H, Lv T, Miao L, Min L, Lin G, Huang L, Yuan J, Jiang Z, Pu X, Rao C, Lv D, Yu Z, Li X, Tang C, Zhou C, Zhang J, Guo H, Chu Q, Meng R, Liu X, Wu J, Zhou J, Zhu Z, Pan W, Dong X, Pang F, Wang K, Yao C, Lin G, Li S, Yang Z, Luo J, Jia H, Nie X, Wang L, Zhu Y, Hu X, Xie Y, Lin X, Cai J, Xia Y, Feng H, Wang L, Du Y, Yao W, Shi X, Niu X, Yuan D, Yao Y, Kang J, Zhang J, Zhang C, Gao W, Huang J, Zhang Y, Sun P, Wang H, Ye M, Wang D, Wang Z, Wan B, Lv D, Yu G, Shi L, Xia Y, Gao F, Zhang X, Xu T, Zhou W, Wang H, Liu Z, Yang N, Wu L, Wang Q, Wang G, Hong Z, Wang J, Fang M, Fang Y, Zhang Y, Song Y, Ma S, Fang W, Lu Y. Zhang S, et al. Among authors: chu q. Thorac Cancer. 2023 Jan;14(1):91-104. doi: 10.1111/1759-7714.14743. Epub 2022 Nov 28. Thorac Cancer. 2023. PMID: 36444143 Free PMC article.
Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis.
Chen P, Zuo H, Xiong H, Kolar MJ, Chu Q, Saghatelian A, Siegwart DJ, Wan Y. Chen P, et al. Among authors: chu q. Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):580-585. doi: 10.1073/pnas.1614035114. Epub 2017 Jan 3. Proc Natl Acad Sci U S A. 2017. PMID: 28049847 Free PMC article.
These findings uncover the lactate-Gpr132 axis as a driver of breast cancer metastasis by stimulating tumor-macrophage interplay, and reveal potential new therapeutic targets for breast cancer treatment....
These findings uncover the lactate-Gpr132 axis as a driver of breast cancer metastasis by stimulating tumor-macrophage interplay, and reveal …
80 results